A kidney cancer where both checkpoint engagement and oncoprotein activation have been validated as functional biomarkers.
The PI3K/Akt pathway is hyperactivated in many ccRCC tumors due to VHL loss and PTEN alterations. However, measuring pathway activation proved challenging until FRET-based approaches.
Using amplified FRET (aFRETLoading...) to detect Akt-PIP3 interaction–the conformational change indicating kinase activation–researchers demonstrated that activation state predicts patient survival with p=0.002, while conventional phospho-Akt IHC showed no correlation (p=0.548).
The Study: In 60 kidney cancer patients, amplified FRET measured whether Akt was activated.
The Results:
• Akt ACTIVATION correlated with poor survival: P=0.002
• Akt EXPRESSION (by IHC) showed NO correlation: P=0.548
This confirmed in a second cancer type what was found in breast cancer.
ccRCC is unique in having two independent functional biomarkerLoading... validations: oncoprotein activation (Akt) and checkpoint engagement (PD-1/PD-L1Loading...). This demonstrates the broad applicability of FRETLoading...-based functional measurements across different biological contexts.
As immunotherapy becomes standard in ccRCC, the ability to quantify both pathway activation and immune checkpointLoading... states in the same tissue offers unprecedented precision for treatment selection.
Two Validations in One Cancer: ccRCC provided proof for both intracellular (Akt) and intercellular (PD-1/PD-L1) functional biomarkers.
Key Finding: iFRET detected PD-1/PD-L1 engagement in 10 of 11 patients labeled "PD-L1 negative" by standard IHC. These patients had functional immune suppression that standard tests missed.
Dual Validation: Clear cell RCC provided critical validation across both checkpoint and kinase targets.
PKB/Akt (2017): In 60 ccRCC patients, amplified FRET-measured Akt activation correlated with poor overall survival (HR 0.228[2], P=0.002[2]). IHC-measured expression showed no correlation (P=0.548).
PD-1/PD-L1 (2020): iFRET detected checkpoint engagement in 10 of 11 patients classified as "PD-L1 negative"[3] by IHC.
Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...
Kidney cancer proof: ccRCC validated the functional biomarker approach for two different targets. Akt activation predicted survival (expression didn't). PD-1/PD-L1 engagement was detected in patients labeled "negative" by standard testing.
